Lannett Co. (LCI) Gets FDA Aproval for Phentermine HCl ANDA
Lannett Company, Inc. (AMEX: LCI) today announced that it has received approval from the U.S. Food and Drug Administration (FDA) of its supplemental Abbreviated New Drug Application (ANDA) for Phentermine HCl Capsules, 15 mg. Sales of Phentermine HCl Capsules, 15 mg, at Average Wholesale Price (AWP) were approximately $11 million for the year ending December 2011, according to Wolters Kluwer. Additional sales of this drug are made through bariatric centers. The company expects to commence shipping the product shortly.
Phentermine Hydrochloride (HCl) is indicated for the short-term management of obesity.
Get immediate access to market moving news and alerts with StreetInsider.com Premium - FREE TRIAL!
Phentermine Hydrochloride (HCl) is indicated for the short-term management of obesity.
Get immediate access to market moving news and alerts with StreetInsider.com Premium - FREE TRIAL!
You May Also Be Interested In
- Auxilium (AUXL) Files Suit Against Watson (WPI) Over Testim 1% Gel
- Bayer, Onyx Pharma (ONXX) Say Nexavar Missed Primary Endpoint in Phase 3
- Mylan (MYL) Launches Generic Bonviva Tabs (RHHBY) in Italy & the U.K.
Create E-mail Alert Related Categories
Corporate News, FDASign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
